NCT03651895View on ClinicalTrials.gov

Metformin to Reduce Airway Glucose in COPD Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

June 1, 2023

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Metformin

The Drug was administered 500 mg twice daily for one week and increased to 1g twice daily for the reminder of the 3 months.

DRUG

Placebo

Placebo

Trial Locations (1)

W2 1NY

Imperial College Respiratory Research Unit, St Mary's Hospital, London

All Listed Sponsors
lead

Imperial College London

OTHER